BiotechTube

Rosnilimab + Placebo

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Dec 22, 2021 → Mar 19, 2023

NCT ID
NCT05205070

About Rosnilimab + Placebo

Rosnilimab + Placebo is a phase 2 stage product being developed by AnaptysBio for Alopecia Areata. The current trial status is unknown. This product is registered under clinical trial identifier NCT05205070. Target conditions include Alopecia Areata.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06127043Phase 2Active
NCT06041269Phase 2Active
NCT05205070Phase 2UNKNOWN

Competing Products

20 competing products in Alopecia Areata

See all competitors
ProductCompanyStageHype Score
BaricitinibEli LillyPhase 2
52
CTP-543Sun PharmaceuticalPhase 2/3
65
CTP-543Sun PharmaceuticalPhase 3
77
Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2/3
65
Baricitinib 4 MG Oral TabletEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
minoxidilJohnson & JohnsonPhase 3
77
5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3
77
Minoxidil + vehicle of 5% Minoxidil topical foamJohnson & JohnsonPhase 2
52
5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3
77
Upadacitinib + Upadacitinib PlaceboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 3
77
Secukinumab + PlaceboNovartisPhase 2
52
DaxdilimabAmgenPhase 2
51
RitlecitinibPfizerPre-clinical
22
LITFULOPfizerPre-clinical
22
RitlecitinibPfizerPre-clinical
22
Ritlecitinib higher dose + Ritlecitinib lower dose + PlaceboPfizerPhase 3
76

Other Products from AnaptysBio

Rosnilimab + PlaceboPhase 2
47
Rosnilimab + PlaceboPhase 2
47
Etokimab + Placebo + Mometasone Furoate Nasal SprayPhase 2
47
ANB032 + PlaceboPhase 2
47
Etokimab + PlaceboPhase 2
47